Not a good buy right now for an impatient entry: price is extended/overbought (RSI_6 ~85.6) and sitting near resistance, which skews near-term risk to a pullback.
Despite improving momentum (positive/expanding MACD), there is no Intellectia buy signal today to justify chasing strength.
Options positioning is extremely call-heavy (Put/Call OI ~0.01), but volume is very thin—more “skew” than broad conviction.
With earnings on 2026-02-17 (after hours) and the latest quarter showing sharp profit/EPS deterioration, the risk/reward favors waiting rather than buying immediately.
Pre-market 86.89 is just above R1 (86.531) and below R2 (88.747) → buying here means buying into resistance.
Pattern-based forward bias: similar-pattern model implies ~-3.01% next week and ~-8.36% next month (near-term drift skewed lower).
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning: Put OI 43 vs Call OI 3009 → extremely bullish/skewed to calls (very low put/call).
Volume: only 3 calls traded and 0 puts today → sentiment signal is weak due to low activity.
Volatility: IV30 ~35.13 vs historical vol ~21.55 → options are pricing elevated uncertainty/premium.
IV context: IV percentile ~63.75 (moderately high vs its history), while IV rank ~8.63 suggests not extreme versus the past year range.
Technical Summary
Sell
4
Buy
11
Positive Catalysts
Technical momentum is currently positive (expanding MACD), suggesting buyers still have control in the short run.
Analyst coverage: Freedom Capital initiated Buy with $93 PT, explicitly calling IOSP undervalued and highlighting upside from new products or opportunistic M&A.
Options open interest is heavily call-skewed, which can provide a supportive sentiment backdrop.
Potential catalyst ahead: QDEC 2025 earnings on 2026-02-17 after hours (could re-rate if margins/EPS rebound).
Neutral/Negative Catalysts
at/near resistance increases the probability of a near-term dip—bad timing for an impatient entry.
Gross margin: 26.41%, down 5.64% YoY (margin pressure is the key negative trend).
Setup into next earnings: Street expects QDEC 2025 EPS ~1.26 (2026-02-17); the “buy” case needs clear margin/earnings rebound versus the weak Q3 print.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent analyst activity: [2025-11-17] Freedom Capital initiated coverage with a Buy rating and a $93 price target.
Trend: only one cited action (initiation), so coverage is constructive but not broad/confirmed by multiple upward revisions.
Wall Street pro view: undervalued specialty chemicals name with potential upside from new products and/or M&A.
Wall Street con view (implied by fundamentals): recent earnings/margins appear to be bottoming but not yet proven—profitability volatility is the central concern.
Influential/politician activity: No recent congress trading data available; hedge funds and insiders are neutral (no notable recent accumulation/distribution).
Wall Street analysts forecast IOSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IOSP is 93 USD with a low forecast of 93 USD and a high forecast of 93 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast IOSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IOSP is 93 USD with a low forecast of 93 USD and a high forecast of 93 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 85.990
Low
93
Averages
93
High
93
Current: 85.990
Low
93
Averages
93
High
93
Freedom Capital
initiated
$93
AI Analysis
2025-11-17
Reason
Freedom Capital
Price Target
$93
AI Analysis
2025-11-17
initiated
Reason
Freedom Capital initiated coverage of Innospec with a Buy rating and $93 price target, calling the company an "undervalued" specialty chemicals maker. The firm said it sees potential upside from either new product offerings or opportunistic M&A. Freedom Capital noted that the stock's recent underperformance along with its bottoming earnings "create an attractive risk-reward tradeoff."
